Live30 webinars pack the latest innovations and applications into a data-rich 30-minute session.
Can ADC manufacturers increase output while maintaining product quality, operator safety, and process robustness? As ADC production spans multiple upstream and downstream operations, inefficiencies at any stage can raise costs, reduce flexibility, and place valuable product at risk.
This webinar presents two real-world case studies addressing performance across the workflow. The first, from a leading CDMO, shows how a fully connected continuous manufacturing process using alternating tangential flow (ATF) perfusion can achieve up to 10X higher productivity and up to 80% lower production costs than fed-batch processing.
The second examines how single-use tangential flow filtration (TFF) systems perform in downstream ADC processing when exposed to commonly used organic solvents. Together, the case studies show how advances in upstream intensification and downstream filtration can support more efficient ADC manufacturing processes, from antibody production through final processing.
Attend this webinar to:
- Examine CDMO data comparing continuous manufacturing with ATF perfusion against a fed-batch baseline, achieving up to 10X higher productivity and up to 80% lower production costs
- Understand how higher cell densities and intensified upstream manufacturing processes can increase antibody output and process efficiency for ADC production
- Learn how single-use TFF systems maintain low levels of extractables in the presence of DMSO and DMAC, helping preserve ADC quality and integrity
- Understand how self-contained single-use TFF systems can reduce product loss and limit operator exposure to cytotoxic material during downstream processing
Daniel Forsey
Senior Field Applications Scientist at Repligen
Dan Forsey is a Senior Field Applications Scientist at Repligen, supporting customers across Europe in the development and optimization of bioprocessing workflows.
With a background in biochemistry and extensive experience in downstream process development, Dan has worked across a wide range of biologics, including proteins, antibodies, and gene therapy modalities. In his current role, he partners closely with process development and manufacturing teams to implement scalable solutions in filtration and purification, with a focus on tangential flow filtration and related technologies.